This is Part 1 of a three-part series on biocompatibility justifications for medical device manufacturers. Part 2 explores the Attachment G opportunity for intact skin contact devices. Part 3 addresses complex scenarios where justifications must work harder.
The Question Every Quality/Regulatory Professional Faces
You're developing a new surface-contacting device using well-known materials. Your team has worked with similar materials before. You ask the inevitable question: "Do we really need full biocompatibility testing, or can we justify it based on existing data?"
It's a fair question. Biocompatibility testing is expensive, time-consuming, and can seem redundant when using materials with decades of safe clinical history. But getting the answer wrong has consequences: rejected submissions, costly retesting, delayed launches, and potentially patient safety issues.
This three-part series provides a framework for thinking about biocompatibility justifications strategically. Part 1 (this post) establishes the foundation: understanding how FDA actually evaluates justifications and where the real opportunities exist. Part 2 will cover the most successful justification pathway—Attachment G for intact skin contact devices. Part 3 will address complex scenarios where justifications must work harder, including long-term contact and compromised skin applications.
To make this concrete throughout the series, we'll work with a recurring example: a silicone-based compression bandage with adhesive backing and polyester fabric, examined under two scenarios—limited intact skin contact (simple bandage) and long-term compromised skin contact (wound management). Same materials, dramatically different regulatory approaches.
How FDA Actually Thinks About Justifications
Before diving into specifics, you need to understand the FDA reviewer's mindset. This is where most failed justifications begin—with incorrect assumptions about what FDA accepts.
The Default Position Is Testing
FDA's starting assumption is that biocompatibility testing is needed. They place the burden of proof on you to demonstrate why testing isn't necessary. This is opposite to what many manufacturers assume.
Equally important: the FDA assesses the biocompatibility of the patient contacting (direct and indirect) parts of the whole device, not just the component materials. Your justification cannot focus solely on materials—it must address the entire device including manufacturing, processing, and final form.
What "Well-Established" Actually Means
Here's where many manufacturers fundamentally misunderstand the standard. "Well-known materials" is not the same as "well-established biocompatibility" in FDA's view.
The FDA generally considers biocompatibility well-established only if a similar device from the same manufacturer, using the same manufacturing and processing methods and used in a similar manner and location in the body, has already been FDA-reviewed and authorized. Manufacturing and processing can alter the physiochemical characteristics of the device, leading to a different biocompatibility response.
Read that carefully. FDA's definition requires:
Same manufacturer (not just similar materials from any manufacturer)
Same manufacturing methods (not just same material)
Same processing methods (cleaning, sterilization, etc.)
Same body contact location and duration
This is much more restrictive than most teams realize. The claim "we use the same silicone everyone uses" doesn't even approach this standard.
The Three-Tier Hierarchy of Evidence
When evaluating your justification, FDA reviewers essentially apply three tiers of evidence strength. Understanding which tier your evidence falls into is critical to predicting success.
Tier 1: Your Company's Identical Cleared Device (Strongest)
This is your gold standard justification. When you have:
Identical materials from same suppliers
Same manufacturing process
Same cleaning and sterilization methods
Same or more demanding clinical use
The reasoning is straightforward: FDA already determined this exact configuration is biocompatible. Nothing has materially changed.
Success rate: Very high. This is the strongest position you can take.
Caveat: "Identical" must be verifiable through documentation. Material changes, supplier changes, manufacturing site changes—any of these can undermine Tier 1 status.
Tier 2: FDA's Attachment G Listing (Moderate)
For intact skin contact devices using specific FDA-approved materials, Attachment G provides a published pathway to skip biocompatibility testing. We'll cover this in detail in Part 2.
Success rate: High when applicable, but applicability is narrow. The materials list is specific, and exclusion criteria disqualify many devices.
Tier 3: Literature and Predicate Device Data (Weakest)
Citing safe clinical history of materials in other devices, ISO certifications from material suppliers, or comparing to predicate devices from other manufacturers.
Success rate: Low without supporting data. While a history of safe clinical use for a material can be supporting evidence, it is rarely sufficient on its own. The justification must demonstrate that the material, processing, and clinical application in your device are essentially identical to the predicate or referenced device—and you typically don't have access to enough information about predicate manufacturing to make that case convincingly.
The Critical Insight: Most rejected justifications come from manufacturers attempting Tier 3 approaches when they need Tier 1 or 2 evidence. Knowing which tier your evidence supports tells you whether to invest in building a justification or to budget for testing.
Why Manufacturers Struggle
The disconnect between what manufacturers think will work and what FDA actually accepts comes from several common misconceptions:
Misconception 1: Material Certifications Are Sufficient
Many manufacturers believe an ISO 10993 certification from a material supplier means biocompatibility is established. This certification typically reflects testing of the raw material under specific conditions—not your finished device after your manufacturing process.
The reality: Material certifications are supporting evidence, not standalone justifications. Your manufacturing process can introduce contaminants, residues, or modifications that affect biocompatibility regardless of starting material quality.
Misconception 2: Same Material = Same Biocompatibility
"Medical-grade silicone" describes a category, not a specific product. Different suppliers produce medical-grade silicones with different additives, fillers, curing systems, and processing. Different grades from the same supplier can have different biocompatibility profiles.
The reality: Material equivalence requires specific grade, supplier, formulation, and processing equivalence. Generic material names are inadequate justification.
Misconception 3: Predicate Devices Establish My Material
If a competitor's device with similar materials is cleared, manufacturers sometimes assume they can leverage that clearance. But you don't have access to the predicate's full manufacturing details, exact material specifications, or processing parameters.
The reality: Without detailed knowledge of predicate manufacturing, you cannot meaningfully claim equivalence. The materials may be similar; the devices may not be.
Misconception 4: Historical Standards Still Apply
Standards have evolved significantly. ISO 10993-1:2018 emphasized chemical characterization and risk-based assessment that older approaches didn't address. ISO 10993-1:2025 strengthens these requirements further.
The reality: Testing approaches acceptable for devices cleared in earlier years may not meet current expectations. Don't assume historical clearance pathways translate to current submissions.
The Strategic Implications
Understanding these standards has major strategic implications for product development:
Material Selection Becomes Regulatory Strategy: Choose materials with the strongest possible justification path. Materials on FDA's Attachment G list, materials with available Master Access Files (MAF), materials used in your existing cleared devices—these choices dramatically affect regulatory burden. Chose your suppliers wisely, suppliers that will work with you on the materials you are considering will make the development and compliance path significantly easier, than those unwilling to work with you on material composition. Slow to respond, or unresponsive suppliers won’t get better over time.
Manufacturing Consistency Has Regulatory Value: Maintaining consistent suppliers, processes, and sterilization methods across your product family enables Tier 1 justifications for new products. Manufacturing variability undermines your strongest justification opportunities.
Documentation Drives Justification Strength: Even Tier 1 justifications require thorough documentation of equivalence. Building justification-ready documentation from project start is far easier than reconstructing it later.
Q-Submissions Reduce Risk: For ambiguous cases, FDA's Q-Submission process provides 75-90 day feedback that can save months of misdirected effort. Use this resource proactively for cases where the justification approach is unclear.
Setting Up Our Compression Bandage Example
Throughout this series, we'll work with a recurring example to make abstract principles concrete:
Device: Silicone-based compression bandage with adhesive backing Materials:
Medical-grade silicone (patient-contacting layer)
Pressure-sensitive acrylic adhesive
Polyester fabric backing
Two Scenarios:
Scenario A: Limited intact skin contact (simple compression bandage, ≤ 24 hours)
Scenario B: Long-term compromised skin contact (chronic wound management, > 30 days)
Same materials, same manufacturer, same manufacturing process. But the clinical applications create fundamentally different regulatory situations.
Preview of where each scenario leads:
For Scenario A (Part 2): Attachment G applies. Justification likely succeeds. The submission package is 5-10 pages. Testing costs of $40,000-$60,000 avoided. Timeline 3-6 months faster than full testing path.
For Scenario B (Part 3): Attachment G doesn't apply. Significant testing required. Justifications can reduce testing burden but won't eliminate it. The submission package runs 60-130 pages with multiple test reports, chemical characterization, and toxicological risk assessment.
The same materials in different applications produce vastly different regulatory paths. Understanding why—and what to do in each case—is the foundation of effective biocompatibility strategy.
Key Takeaways from Part 1
FDA's default position is that testing is needed. The burden of proof falls on you to justify otherwise.
"Well-established biocompatibility" has a narrow technical meaning focused on identical configuration in cleared devices, not material familiarity.
The three-tier evidence hierarchy determines success probability. Tier 1 (your cleared devices) is strongest, Tier 2 (Attachment G) is reliable when applicable, Tier 3 (literature/predicates) usually fails alone.
The manufacturing process matters as much as materials. Same material, different manufacturing = potentially different biocompatibility.
Strategic material selection and manufacturing consistency create regulatory value beyond their direct product impact.
Coming Up in This Series
Part 2: The Attachment G Opportunity—We'll dive deep into FDA's published exemption for intact skin contact devices, including which materials and devices qualify, critical exclusions that disqualify use, step-by-step submission approach, and why our compression bandage Scenario A succeeds with minimal testing.
Part 3: When Justifications Must Work Harder—We'll address the complex cases: long-term contact, compromised skin, mucosal membranes, and devices where Attachment G doesn't apply. Topics include chemical characterization strategy, toxicological risk assessment, leveraging Master Access Files, common failure modes, and why our compression bandage Scenario B requires significant testing.